{'fraction_non_alphanumeric': 0.01669195751138088, 'fraction_numerical': 0.00556398583712696, 'mean_word_length': 5.44299674267101, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
High Resolution Tomographic Analysis of in vitro 3D Glioblastoma Tumor Model under Long-Term Drug Treatment

Glioblastoma multiforme (GBM) is an extremely lethal type of brain tumor as it frequently develops therapeutic resistance over months of chemotherapy cycles. Hence, there is a critical need to provide relevant biological systems to guide the development of new potent personalized drugs but also efficient methodologies that enable personalized prediction of various therapeutic regimens for enhanced patient prognosis. Towards this goal, we report on the development of i) an appropriate in vitro model that mimics the 3D tumor microenvironment and ii) a companion imaging modality that enables to assess this in vitro model in its entirety. More precisely, we developed an integrated platform of bio-printing in vitro 3D GBM models and mesoscopic imaging to monitor tumor growth and invasion along with long-term drug treatment. The newly-developed in vitro 3D model contains tumor spheroids made of patient-derived glioma stem cells with a fluorescent reporter and vascular channels for drug perfusion. The imaging of these thick tissue constructs was performed using our second-Generation Mesoscopic Fluorescence Molecular Tomography (2GMFMT) imaging system which delivered 3D reconstruction of the fluidic channels and the GBM spheroids over the course of pre- and post-drug treatment (up to 70 days). The 2D measurements collected via 2GMFMT was comparable to existing imaging modalities, but 2GMFMT enabled non-sacrificial volumetric monitoring that provided a unique insgiht into the GBM spheroid growth and drug response. Overall, our integrated platform provides customizable in vitro model systems combined with an efficient long-term non-sacrificial imaging for the volumetric change of tumor mass, thus has a great potential in profoundly affecting the drug pipeline for a vast array of pathologies as well as for guiding personalized therapeutic regimen.